← Back to Search

Other

BMS-986369 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body mass index (BMI) of 18.0 through 33.0 kilogram meter squared (kg/m^2), inclusive. BMI = weight kg/height m^2.
Absolute neutrophil counts must be greater than 2,500 per microliter (μL) at screening and Day -1.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 28 days
Awards & highlights

Study Summary

The purpose of the study is to assess mass balance, biotransformation, and excretion of BMS-986369 following study drug administration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])
Maximum observed plasma concentration (Cmax)
+6 more
Secondary outcome measures
Number of participants with adverse events (AEs)
Number of participants with clinical laboratory test abnormalities
Number of participants with electrocardiogram (ECG) abnormalities
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: BMS-986369Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986369
2022
Completed Phase 1
~80

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,629 Previous Clinical Trials
4,126,528 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA granted certification to BMS-986369?

"The safety of BMS-986369 was rated a 1 due to the fact that this is a Phase 1 trial, meaning there has only been minimal testing and research done on it thus far."

Answered by AI

Is eligibility for this medical trial limited to those aged 40 and below?

"The eligibility requirements for this medical trial establish 18 years as the lower limit and 55 years old as the upper boundary."

Answered by AI

Are there any vacancies in this test for participants?

"Reports on clinicaltrials.gov demonstrate that this trial is still enrolling participants, having been initially published on October 20th 2022 and last modified November 27th 2022."

Answered by AI

What is the total enrollment of participants for this trial?

"Affirmative. Per the data on clinicaltrials.gov, this medical study is actively looking for 8 research volunteers from 1 centre and was initially posted on October 20th 2022 before its most recent update in late November of the same year."

Answered by AI

Are there particular criteria for participating in this medical research?

"This trial is open to 8 participants aged between 18 and 55, who are deemed healthy subjects (hs). To guarantee the safety of all involved, additional criteria must be met. These include male gender, body mass index within a certain range, as well as specific values for blood tests results at screening and check-in stages."

Answered by AI
~3 spots leftby Mar 2025